Brief: SillaJen and Transgene enroll first European patient in Phase 3 trial for Pexa-Vec

SillaJen

24/04/2017 16:45

April 24 (Reuters) - SillaJen Inc  215600.KQ : 
    * SillaJen and Transgene announce the enrollment of the first European patient in 
multinational Phase 3 trial for Pexa-Vec in advanced liver cancer 
    * Enrollment of the first European patient triggers a $4 million USD milestone to be paid to 
Sillajen by Transgene 
 
Source text for Eikon:  ID:nPnMsqNPa  
Further company coverage:  215600.KQ ,  TRNG.PA  
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))